Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Significantly Reduce Hypercholesterolemia in Patients on Dialysis (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0440; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Methods We retrospectively evaluated clinical data from a real-world cohort of 21 dialysis pts routinely followed at the Nephrology of Policlinico di Milano and AST Pesaro-Urbino, who initiated therapy with PCSK9i (16 with Evolocumab and 5 Inclisiran).16 pts were undergoing haemodialysis, 5 peritoneal dialysis.Comorbidities, lipid profile, drug safety and CV outcomes were evaluated. Results Mean age was 65 years, 72% males, mean dialysis vintage 4 years.8 pts had a history of CV events, 17 a diagnosis of PAD.In 7 pts, PCSK9i were initiated due to statin intolerance (CPK elevation), while in 14 pts were added to statins/ezetimibe because of inadequate cholesterol control.Median follow-up (FU) was 8±3 months.Following PCSK9i initiation, a rapid and significant improvement in lipid parameters was observed (Figure 1).After 3 months, total cholesterol levels were reduced by 40%, and LDL by 50%.These effects were sustained over time, 36% in total cholesterol and..."
Clinical • Dyslipidemia • Metabolic Disorders • Nephrology
|
|
Matteo Abinti; Federica Tripodi; Valentina Binda; Federico Bari; Gianluca Samele; Sara Samoni; Francesca Zanoni; Giulia Porata; Simone Vettoretti; Marina Di luca; Giuseppe Castellano
|